Validation of the RHL30 digital gene expression assay as a prognostic biomarker for relapsed Hodgkin lymphoma. Calvente L, Tremblay-LeMay R, … Sabatini P, Kridel R. Br J Haematol, 2020.

In this paper, we were able to validate the RHL30 gene expression assay in a series of patients with relapsed Hodgkin lymphoma who were treated at Princess Margaret Cancer Centre. The RHL30 assay allows to identify patients with diverging outcomes post-autologous stem cell transplantation.